Engene Therapeutics Inc. (ENGN) Stock Price & Analysis
Engene Therapeutics Inc. (ENGN) fell 0.55% to USD 1.82 as of September 8, 2026 at 04:14 UTC, according to Nexqual real-time market data.
ENGN last closed at USD 1.83; the session ranged USD 1.78–1.84 on volume of 412,684 shares. Market capitalization is $121.92M, with a 52-week range of USD 1.4–12.25 (NCM). Source: Nexqual, September 8, 2026 at 04:14 UTC.
Key Statistics (as of September 8, 2026 at 04:14 UTC)
| Price | USD 1.82 |
|---|---|
| Change | ▼ 0.55% (down) |
| Previous Close | USD 1.83 |
| Open | USD 1.82 |
| Day Range | USD 1.78 – 1.84 |
| 52-Week Range | USD 1.4 – 12.25 |
| Volume | 412,684 shares |
| Market Cap | $121.92M |
| Exchange | NCM |
Technical Analysis (ENGN)
Nexqual's technical model rates ENGN "NEUTRAL" based on 3 bullish and 2 bearish signals across 128 daily candles, as of September 8, 2026 at 04:14 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 47.4 (neutral) |
| vs SMA50 | Above (USD 1.82) |
| MACD | 0.01 (positive) |
Financial Health Score (ENGN)
Nexqual rates Engene Therapeutics Inc.'s overall financial health "Mixed" across five dimensions, as of September 8, 2026 at 04:14 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $258M cash vs $33M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$110M |
| Efficiency | Critical — ROE -53%, ROA -28.9% |
Leadership (ENGN)
Engene Therapeutics Inc. is led by Ronald H. W. Cooper (age 62), President, CEO & Director, per Nexqual as of September 8, 2026 at 04:14 UTC.
| President, CEO & Director | Ronald H. W. Cooper (age 62) |
|---|---|
| Interim Chief Medical Officer & Director | William J. Grossman (age 55) |
| Co-Founder & Chief Scientific Officer | Anthony T. Cheung (age 53) |
| Chief Technology Officer | Joan Connolly (age 55) |
Major Backers & Investors (ENGN)
Notable institutional backers of Engene Therapeutics Inc. include FCPM III Services B.V., BML Capital Management, LLC, Siren, L.L.C., according to Nexqual as of September 8, 2026 at 04:14 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FCPM III Services B.V. | 14.38% |
| BML Capital Management, LLC | 9.96% |
| Siren, L.L.C. | 9.34% |
| Perceptive Advisors Llc | 7.2% |
| Ameriprise Financial, Inc. | 3.99% |
| Nextech Invest, Ltd. | 3.47% |
| Adar1 Capital Management, LLC | 3.14% |
| Vestal Point Capital, LP | 2.49% |
Source: Nexqual, September 8, 2026 at 04:14 UTC.
From Engene Therapeutics Inc.'s Latest SEC 10-K Filing (filed 2025-12-22)
Key Strengths & Strategy (as disclosed to the SEC)
- enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada.
- The company develops genetic medicines to help patients suffering from bladder cancer.
- Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC).
- Its pipeline includes LEGEND, which is in Phase 2.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LXEO | Lexeo Therapeutics, Inc. | USD 4.89 | ▲ 2.3% |
| PEPG | PepGen Inc. | USD 3.11 | ▼ 2.2% |
| KRRO | Korro Bio, Inc. | USD 12.24 | ▲ 2.26% |
| CGON | CG Oncology, Inc. | USD 74.67 | ▲ 0.11% |
| QTTB | Q32 Bio Inc. | USD 11.99 | ▼ 11.77% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 04:14 UTC. This page is informational and not investment advice.